All In Biotech

Drug Trial Radar · NCT06888921

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC)

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 21, 2025

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Compugen LtdIndustry
Sponsor type
Industry
First posted
Mar 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer? * Does COM701 delay the time to needing a new anti-cancer treatment? * What side effects do participants have when taking COM701? Participants will: * Visit the clinic once every 3 weeks during which the study treatment will be administered intravenously * Undergo various tests and procedures to monitor general health throughout the trial including physical examinations, vital sign measurements (heart rate, blood pressure, breathing, and body temperature), weight measurements, electrocardiography (ECG), blood and urine tests and pregnancy tests if relevant. * Undergo various tests and procedures to assess disease response throughout the trial including tumor imaging by CT scans or MRI to assess the tumor, its location, and size, and the testing of a sample of tumor tissue (from a prior biopsy or a fresh biopsy if feasible, to evaluate tumor response to treatment and to measure levels of tumor markers,

Conditions

  • Ovarian Cancer
  • Ovarian Cancer Recurrent

Interventions

  • COM701Drug

    COM701 will be administered via intravenous (IV) infusion once every 3 weeks.

  • Normal SalineDrug

    Saline will be administered via intravenous (IV) infusion once every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of COM701 as a single agent on progression free survival when administered as a maintenance regimen in participants with relapsed PSOCTime frame: From the date of randomization until the date of disease progression, or date of death from any cause whichever occurs first, assessed up to 2 years

Locations

27 sites in 3 countries. Site status is shown where the registry gives one.

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Northwestern Memorial Hospital

    Warrenville, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Corewell Health

    Grand Rapids, Michigan

  • Memorial Sloan Kettering Cancer Center- Main Campus

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run

    Hilliard, Ohio

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • UPMC Magee- Womens Hospital

    Pittsburgh, Pennsylvania

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • UVA Comprehensive Cancer Center

    Charlottesville, Virginia

  • Centre Oscar Lambret

    Lille, France

  • Institut Paoli-Calmettes

    Marseille, France

  • Hospices Civils de Lyon- Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Centre Eugene Marquis

    Rennes, France

  • Institut de Cancerologie de l'Ouest- Site Rene Gauducheau

    Saint-Herblain, France

  • Gustave Roussy

    Villejuif, France

  • Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz

    Besançon, France, France

  • Oncopole Claudius Regaud

    Toulouse, France, France

  • Assuta Medical Center

    Ashdod, Israel

  • Rambam Health Care Campus

    Haifa, Israel

  • The Edith Wolfson Medical Center

    Holon, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Hadassah, University Hospital Ein Kerem

    Jerusalem, Israel

  • The Chaim Sheba Medical Center

    Ramat Gan, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.